GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Evaluation of Pazopanib on Bleeding in Subjects With Hereditary Haemorrhagic Telangiectasia

Phase 2

Terminated

Conditions: Telangiectasia, Hereditary Hemorrhagic

Interventions: Drug: Pazopanib
Drug: Placebo

First Posted Date: 2014-07-30

Last Posted Date: 2017-07-06

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 7

Registration Number: NCT02204371

Locations: 🇨🇦
GSK Investigational Site, Toronto, Ontario, Canada

A Methodology Study to Evaluate a Sitting Knee Measuring Device in Assessing Growth in Indian Children.

Phase 1

Completed

Conditions: Nutritional Status

Interventions: Dietary Supplement: Nutritional supplement with micronutrient
Dietary Supplement: Nutritional supplement without micronutrient

First Posted Date: 2014-07-28

Last Posted Date: 2018-01-12

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 109

Registration Number: NCT02201225

Locations: 🇮🇳
GSK Investigational Site, Bangalore, India

A Pilot Study to Determine the Relative Bioavailability of Mosapride 5mg From Two Candidate Formulations of GR107719B Relative to One 5mg Tablet of Reference Mosapride Citrate (GASMOTIN™) in Healthy Adult Human Subjects Under Fasting Conditions

Phase 1

Completed

Conditions: Gastritis

Interventions: Drug: Reference mosapride citrate (GASMOTIN)
Drug: GR107719B (Formulation 1)
Drug: GR107719B (Formulation 2)

First Posted Date: 2014-07-28

Last Posted Date: 2017-05-15

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 18

Registration Number: NCT02201316

Locations: 🇮🇳
GSK Investigational Site, Hyderabad, India

A Single Oral Escalating Dose Study of GSK2140944 in Healthy Volunteers

Phase 1

Completed

Conditions: Infections, Respiratory Tract

Interventions: Drug: GSK2140944
Other: Placebo

First Posted Date: 2014-07-28

Last Posted Date: 2017-06-12

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 48

Registration Number: NCT02202187

Locations: 🇺🇸
GSK Investigational Site, Minneapolis, Minnesota, United States

Evaluation of Danirixin (GSK1325756) Inhibition of CD11b Cell Surface Expression

Phase 1

Completed

Conditions: Infections, Respiratory Syncytial Virus

Interventions: Other: CXCL1
Drug: Danirixin

First Posted Date: 2014-07-28

Last Posted Date: 2017-05-09

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 40

Registration Number: NCT02201303

Locations: 🇺🇸
GSK Investigational Site, Syracuse, New York, United States

Pharmacokinetics Study Comparing Topical Diclofenac/Menthol Gels With Voltaren Gel and Oral Diclofenac Sodium

Phase 1

Completed

Conditions: Pain

Interventions: Drug: Diclofenac sodium
Drug: Menthol

First Posted Date: 2014-07-28

Last Posted Date: 2017-06-29

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 18

Registration Number: NCT02201238

Locations: 🇺🇸
GSK Investigational Site, Buffalo, New York, United States

A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 Administered With Metformin to Type 2 Diabetes Patients

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: GSK2330672
Drug: Placebo
Drug: Sitagliptin
Drug: Metformin

First Posted Date: 2014-07-28

Last Posted Date: 2017-11-06

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 70

Registration Number: NCT02202161

Locations: 🇺🇸
GSK Investigational Site, San Antonio, Texas, United States

The Effect of Experimental Dentifrices on Remineralization of Caries Lesions In-situ

Not Applicable

Completed

Conditions: Oral Hygiene

Interventions: Drug: Sodium fluoride (250 ppm)
Drug: Sodium fluoride (1150 ppm)
Drug: Sodium fluoride (1426 ppm) + zinc base A
Drug: Sodium fluoride (1426 ppm)
Drug: Fluoride (0 ppm)
Drug: Sodium fluoride (1426 ppm) + zinc base B